Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2025)

Indivior Pharmaceuticals has reported Enterprise Value over the past 5 years, most recently at -$195.0 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$195.0 million for Q4 2025, up 39.06% from a year ago — trailing twelve months through Dec 2025 was -$195.0 million (up 39.06% YoY), and the annual figure for FY2025 was -$195.0 million, up 39.06%.
  • Enterprise Value for Q4 2025 was -$195.0 million at Indivior Pharmaceuticals, up from -$445.0 million in the prior quarter.
  • Over the last five years, Enterprise Value for INDV hit a ceiling of -$195.0 million in Q4 2025 and a floor of -$1.1 billion in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$427.5 million (2023), compared with a mean of -$531.0 million.
  • Biggest five-year swings in Enterprise Value: grew 18.97% in 2022 and later surged 54.09% in 2023.
  • Indivior Pharmaceuticals' Enterprise Value stood at -$1.1 billion in 2021, then increased by 18.97% to -$893.0 million in 2022, then soared by 54.09% to -$410.0 million in 2023, then increased by 21.95% to -$320.0 million in 2024, then soared by 39.06% to -$195.0 million in 2025.
  • The last three reported values for Enterprise Value were -$195.0 million (Q4 2025), -$445.0 million (Q3 2025), and -$510.0 million (Q2 2025) per Business Quant data.